COST-EFFECTIVENESS OF SYSTEMATIC SCREENING AND TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) IN UNITED STATES

被引：0
|
作者：
Lau, Anson Tsz Chun [1 ]
DiDomenico, Robert J., Jr. [1 ]
Kim, Kibum [1 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106-003
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 39 (2) : 297 - 305
  • [42] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [43] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    HEART, 2018, 104 (12) : 1006 - 1013
  • [44] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [45] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [46] WHAT'S THE COST OF HOSPITALISATIONS DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES?
    Shamliyan, T.
    Nambiar, S.
    Martin, A.
    VALUE IN HEALTH, 2019, 22 : S552 - S553
  • [47] Cost-Effectiveness of Empagliflozin for Patients With Heart Failure Irrespective of Ejection Fraction in England
    Cheen, M.
    Gaultney, J.
    Bellanca, L.
    Linden, S.
    VALUE IN HEALTH, 2022, 25 (12) : S150 - S150
  • [48] Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF)
    Fisher, Shane Michael
    Murally, Anjali Rosanna
    Rajabally, Zahra
    Almas, Talal
    Azhar, Maimoona
    Cheema, Faisal H.
    Malone, Andrew
    Hasan, Babar
    Aslam, Nadeem
    Saidi, Jemil
    O'Neill, Jim
    Hameed, Aamir
    HEART FAILURE REVIEWS, 2024, 29 (01) : 257 - 276
  • [49] Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF)
    Shane Michael Fisher
    Anjali Rosanna Murally
    Zahra Rajabally
    Talal Almas
    Maimoona Azhar
    Faisal H. Cheema
    Andrew Malone
    Babar Hasan
    Nadeem Aslam
    Jemil Saidi
    Jim O’Neill
    Aamir Hameed
    Heart Failure Reviews, 2024, 29 : 257 - 276
  • [50] Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
    Kolovos, Spyros
    Bellanca, Leana
    Groyer, Harinala
    Rosano, Giuseppe
    Gaultney, Jennifer
    Linden, Stephan
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2023, 24 (10) : 758 - 764
12345